Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Expected to Post Earnings of $2.47 Per Share

Share on StockTwits

Analysts expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to post earnings of $2.47 per share for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Alexion Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $2.37 and the highest estimate coming in at $2.61. Alexion Pharmaceuticals reported earnings of $2.02 per share during the same quarter last year, which indicates a positive year over year growth rate of 22.3%. The firm is expected to issue its next quarterly earnings report on Wednesday, October 23rd.

According to Zacks, analysts expect that Alexion Pharmaceuticals will report full year earnings of $9.90 per share for the current financial year, with EPS estimates ranging from $9.72 to $10.31. For the next fiscal year, analysts anticipate that the company will report earnings of $10.74 per share, with EPS estimates ranging from $9.18 to $12.31. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.51. The company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. Alexion Pharmaceuticals’s revenue was up 15.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.07 EPS.

Several equities analysts have weighed in on ALXN shares. Goldman Sachs Group restated a “neutral” rating and issued a $142.00 price objective on shares of Alexion Pharmaceuticals in a report on Thursday, May 23rd. JPMorgan Chase & Co. began coverage on shares of Alexion Pharmaceuticals in a report on Wednesday, July 31st. They issued an “overweight” rating and a $172.00 price objective on the stock. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 24th. TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a report on Thursday, April 25th. Finally, Raymond James upped their price objective on shares of Alexion Pharmaceuticals from $164.00 to $168.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the stock. Alexion Pharmaceuticals has an average rating of “Buy” and a consensus target price of $162.88.

In other Alexion Pharmaceuticals news, insider Aradhana Sarin sold 578 shares of the stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $132.00, for a total transaction of $76,296.00. Following the sale, the insider now directly owns 30,201 shares in the company, valued at approximately $3,986,532. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Indrani Lall Franchini sold 4,500 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $132.78, for a total transaction of $597,510.00. Following the sale, the executive vice president now owns 29,627 shares in the company, valued at $3,933,873.06. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 428,567 shares of company stock worth $53,420,869. 4.08% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Investors Research Corp purchased a new stake in shares of Alexion Pharmaceuticals in the 1st quarter valued at approximately $27,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter valued at approximately $28,000. Redhawk Wealth Advisors Inc. purchased a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter valued at approximately $29,000. Ossiam purchased a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter valued at approximately $32,000. Finally, Thor Advisors LLC purchased a new stake in shares of Alexion Pharmaceuticals in the 1st quarter valued at approximately $34,000. Institutional investors own 93.77% of the company’s stock.

NASDAQ:ALXN opened at $111.47 on Friday. The company has a quick ratio of 3.56, a current ratio of 4.04 and a debt-to-equity ratio of 0.26. The firm has a market cap of $24.99 billion, a price-to-earnings ratio of 15.72, a price-to-earnings-growth ratio of 1.05 and a beta of 1.65. The company has a 50-day moving average price of $120.35. Alexion Pharmaceuticals has a 1-year low of $92.56 and a 1-year high of $141.86.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Article: Leveraged Buyout (LBO) Explained

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zoetis Inc  Receives Average Rating of “Buy” from Analysts
Zoetis Inc Receives Average Rating of “Buy” from Analysts
CVS Health Corp  Stock Holdings Lifted by Private Advisor Group LLC
CVS Health Corp Stock Holdings Lifted by Private Advisor Group LLC
Private Advisor Group LLC Sells 5,575 Shares of Vanguard Mid-Cap Growth ETF
Private Advisor Group LLC Sells 5,575 Shares of Vanguard Mid-Cap Growth ETF
Private Advisor Group LLC Sells 188,195 Shares of SPDR Blackstone / GSO Senior Loan ETF
Private Advisor Group LLC Sells 188,195 Shares of SPDR Blackstone / GSO Senior Loan ETF
Private Advisor Group LLC Increases Holdings in Schwab US Large-Cap ETF
Private Advisor Group LLC Increases Holdings in Schwab US Large-Cap ETF
Private Advisor Group LLC Has $5.53 Million Stock Position in Illinois Tool Works Inc.
Private Advisor Group LLC Has $5.53 Million Stock Position in Illinois Tool Works Inc.


© 2006-2019 Ticker Report